Needham Reiterates Buy on Neumora Therapeutics, Maintains $23 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia has reiterated a Buy rating on Neumora Therapeutics (NASDAQ:NMRA) and maintained a price target of $23.
September 12, 2024 | 5:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Ami Fadia has reiterated a Buy rating on Neumora Therapeutics and maintained a price target of $23, indicating confidence in the company's potential.
The reiteration of a Buy rating and maintenance of a $23 price target by a reputable analyst suggests a positive outlook for Neumora Therapeutics. This can boost investor confidence and potentially lead to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100